United Arab Emirates · application pack

Dr. Dipika Ramdas Kalambhe — UAE Applications

Seven targets across Abu Dhabi, Dubai, Sharjah and Ras Al Khaimah. Every posting referenced here was opened and read on 1 August 2026. Each card holds the position, the link to the original circular, an honest read on the chances, the CV to send, and the email text ready to copy.

7Targets

2Live adverts

5Speculative

—Days to UAEU

4Emirates

Only two of the seven have a job circular, and one of those is a long shot. That is the finding, not an omission. Cards marked Live advert link to the original posting. Cards marked Cold email or Speculative have no advertisement to link to, because nothing is posted — they are direct approaches to a named scientist or employer, and each one says so on its action row. In drug delivery most posts are filled by direct contact before they are ever advertised, so this is the normal route into the field, not a fallback.

Built 1 August 2026 · deadlines recompute from your system clock · tick-boxes are saved in this browser

Filter 7 shown

Do these first

2 of 6

One has a deadline; the other is the closest laboratory in the Gulf to her actual work. Everything else can wait a week without cost.

United Arab Emirates University · Al Ain Top target Live advert Abu Dhabi

Postdoctoral Fellow — Targeted drug delivery of epigenetic inhibitors

Closes 31 Aug 2026 Term 24 months + medical insurance Verified open, 1 Aug 2026

Why this is the one. An epigenetic inhibitor is a drug that changes which genes a cell switches on, rather than attacking the cell directly. JQ1 — one of the two drugs in her thesis — is exactly that kind of drug. Her whole doctorate was building a carrier to deliver JQ1 into a tumour, because on its own it barely dissolves, clears too fast, and reaches healthy tissue. The advert's subject is a one-line description of her PhD. It would be hard to find a closer match anywhere in the Emirates.

The gap, and it is real. They ask for a PhD in Chemistry and "extensive hands-on experience in multi-step organic synthesis" — reaction design, route optimisation, NMR. She is a formulation scientist, not a synthetic chemist: she does not make molecules, she delivers them. The letter opens with this rather than burying it, and argues the project needs both halves. Odds: good if the group has synthesis covered and needs formulation; low if they want a pure synthetic chemist. Worth one application either way.

↗ Open the circular ↓ CV — Academic (PDF) ↓ CV — ATS for portal (PDF) ☰ Full notes

Cover letter — ready to copy

paste into the portal, or convert to PDF

Dr. Dipika Ramdas Kalambhe, Ph.D.
doctordipikaoffical555@gmail.com | +971 50 965 9103 | WhatsApp +91 97667 87348
ORCID 0009-0007-0026-4638

1 August 2026

Search Committee
Postdoctoral Fellow — Targeted Drug Delivery of Epigenetic Inhibitors
United Arab Emirates University
Al Ain, United Arab Emirates

Dear Members of the Search Committee,

I am applying for the Postdoctoral Fellow position on targeted drug delivery systems for potent epigenetic inhibitors.

I want to open with the part of my application you will want to test, rather than leave it to the last paragraph. I am not a synthetic chemist. My doctorate is in pharmaceutics, and I do not carry out multi-step organic synthesis or structure elucidation by NMR. If the project requires someone to design and build the inhibitors themselves, I am not that person, and I would rather say so now.

What I bring is the other half of the problem in your title, and I have already solved it for this exact class of compound. My doctoral work at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, was the co-delivery of shikonin and JQ1 — a BET bromodomain inhibitor — to triple-negative breast tumours. JQ1 is precisely the kind of potent epigenetic inhibitor your advertisement describes, and it fails in vivo for reasons that are pharmaceutical rather than chemical: poor aqueous solubility, rapid clearance, and exposure of healthy tissue at the concentrations needed for effect. Delivery is the bottleneck between a compound that works in a dish and one that works in an animal.

I designed a mesoporous polydopamine-based Pickering emulsion that carries both agents in a single particle, resolving their incompatible solubility and release requirements. In triple-negative breast cancer models it suppressed primary tumour growth and lung metastasis, and we established the mechanism as apoptosis induction combined with blockade of both epithelial-mesenchymal transition and vasculogenic mimicry — three separate escape routes closed at once. The work is published in Acta Pharmacologica Sinica (46:3314-3326), where I am joint first author with equal contribution formally recorded. I subsequently incorporated the same formulation into a thermosensitive hydrogel placed at the resection site, to address recurrence in the post-surgical window.

I also published a first-author review in Drug Delivery and Translational Research on nanotechnology-based delivery strategies for modulating the tumour immune microenvironment, which required me to survey this problem across the field rather than only in my own hands.

Practically, I would arrive able to contribute from the first week on:

- carrier design and optimisation — drug loading, encapsulation efficiency, particle size and polydispersity, surface charge, colloidal stability, controlled release;
- physicochemical characterisation — DLS and zeta potential, TEM and SEM, HPLC and UV-Vis assay and release testing, fluorescence and confocal microscopy;
- the biology that shows whether delivery worked — cellular uptake, viability and apoptosis assays, Western blot, RT-qPCR, ELISA, flow cytometry, immunofluorescence and immunohistochemistry;
- and the full in vivo programme — study design and animal ethics approval, dosing, tumour and body-weight monitoring, biodistribution, histopathology and organ toxicity.

That range is the reason I am worth interviewing. A delivery project does not have to change hands between the person who formulates, the person who runs the assays and the person who runs the animal work. I have carried projects across all three.

Your advertisement also names neurological disease. I have not worked on the blood-brain barrier, and I would be learning that literature rather than teaching it. I mention it for the same reason I opened with the synthesis gap: I would rather be trusted on the things I do claim.

I hold seven peer-reviewed publications attracting 324 citations (h-index 3, Google Scholar, July 2026) and one filed Indian patent (App. No. 202421042057) on a transdermal formulation, which I took from concept through in vitro efficacy and in vivo safety evidence to filing. My doctorate was funded throughout by two competitive international fellowships, the ANSO Young Talent Fellowship and the Belt and Road Government Fellowship.

I would welcome the chance to discuss how the delivery side of this project might be built out, and I am available for interview at short notice.

Yours sincerely,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Research statement — required by this application

they will not consider the application without it

RESEARCH STATEMENT
Dr. Dipika Ramdas Kalambhe, Ph.D.
Applicant — Postdoctoral Fellow, Targeted Drug Delivery of Epigenetic Inhibitors
United Arab Emirates University, August 2026

1. THE PROBLEM I WORK ON

Potent epigenetic inhibitors do not usually fail because they are weak. They fail because they cannot be delivered.

BET bromodomain inhibitors are the clearest example. JQ1 silences MYC-driven transcriptional programmes at nanomolar concentrations in culture, and yet its translation has been limited by poor aqueous solubility, a short half-life, and a therapeutic window narrowed by exposure of healthy tissue. The same pattern recurs across the class. The chemistry is not the limiting step; the pharmaceutics is.

My work sits at that boundary. I design carriers that hold a poorly soluble, rapidly cleared compound long enough, and release it in the right place, for the biology to matter.

2. WHAT I ESTABLISHED DURING MY DOCTORATE

At the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, I developed a mesoporous polydopamine-based Pickering emulsion that co-delivers two agents with fundamentally incompatible formulation requirements: shikonin, a naphthoquinone natural product that inhibits PKM2 and suppresses tumour glycolysis, and JQ1, a BET bromodomain inhibitor.

Co-delivery in a single particle was the point, not a convenience. Two agents administered separately reach a given tumour cell at different times and in different ratios; a single carrier holds the ratio fixed to the point of release.

The result in triple-negative breast cancer models was suppression of both primary tumour growth and lung metastasis. Mechanistically we showed the combination:

- induced apoptosis;
- blocked epithelial-mesenchymal transition, the programme by which carcinoma cells acquire the motility to leave the primary site;
- and blocked vasculogenic mimicry, in which tumour cells form their own perfusion channels and so escape therapies aimed at normal blood-vessel formation.

Closing three escape routes at once is what produced the metastatic effect, and it is an argument for combination delivery rather than for either drug alone.

This was published in Acta Pharmacologica Sinica 46(12):3314-3326, where I am joint first author, with equal contribution formally recorded.

I then extended the platform into a thermosensitive hydrogel intended for placement at the resection site, addressing the post-surgical window in which residual disease seeds recurrence — a setting where systemic dosing is poorly suited and local, sustained release is the natural answer.

3. WHAT I WOULD PROPOSE HERE

I would join the delivery side of the group's programme, and I would expect to be most useful in three places.

A. Carrier design for the group's inhibitor series. Systematic optimisation of loading, encapsulation efficiency, size distribution, surface charge, colloidal stability and release profile — treating these as coupled variables against a defined target product profile rather than optimising one at a time. Mesoporous and polydopamine-based carriers are where my hands are best, but the method transfers across carrier chemistries.

B. Establishing that delivery actually happened. A formulation result is not a delivery result. Cellular uptake, intracellular localisation by confocal microscopy, target engagement by Western blot and RT-qPCR, and biodistribution in vivo — so that a negative efficacy result can be attributed to the compound rather than to the carrier, which is a distinction that saves a great deal of time.

C. The in vivo package. Study design and ethics approval, dosing and route selection, tumour and body-weight monitoring, terminal tissue collection, histopathology and organ-toxicity readouts. I have run this end to end, independently.

Two directions I would want to develop with the group: whether local and sustained delivery — the hydrogel approach — widens the therapeutic window for epigenetic inhibitors whose systemic toxicity is dose-limiting; and whether the immune consequences of epigenetic inhibition can be exploited by controlling where and when the drug appears, which follows from my first-author review on nanocarrier modulation of the tumour immune microenvironment.

4. WHAT I DO NOT BRING

I am a formulation scientist, not a synthetic chemist. I do not perform multi-step organic synthesis, route optimisation or structural elucidation by NMR. If the group's synthesis capability is already in place, I complement it; if the post is fundamentally a synthesis post, I am the wrong applicant and would rather that be clear at the outset.

I have also not worked on delivery across the blood-brain barrier. Given the advertisement mentions neurological disease, I would be learning that literature, not leading it, in the first year.

5. RECORD

Seven peer-reviewed publications, 324 citations, h-index 3 (Google Scholar, July 2026). Three as first or joint first author. One filed Indian patent (App. No. 202421042057) on a transdermal delivery system, taken from formulation concept through in vitro efficacy and in vivo safety evidence to filing. Doctoral research funded throughout by the ANSO Young Talent Fellowship and the Belt and Road Government Fellowship.

Full publication list with DOIs is in the accompanying CV.

Checklist

Re-open the posting and confirm the closing date has not moved
Register on the UAEU jobs portal
Convert cover letter and research statement to PDF
Upload the ATS CV if the portal parses files; otherwise the designed CV
Submit well before 31 August — portals fail on the last day
Save the reference number the portal returns

NYU Abu Dhabi · Magzoub Lab, Biology Top target Cold email Abu Dhabi

Postdoctoral researcher — speculative approach to Dr Mazin Magzoub

Contact mm6432@nyu.edu Deadline none — send now Verified in post, 1 Aug 2026

The closest laboratory in the Gulf to her actual work. The group develops peptides, polymeric nanoparticles and mesoporous carriers to deliver antitumour agents into cells. Two of their papers sit almost on top of her thesis: pH-responsive polymeric nanoparticles for targeted delivery of anticancer therapeutics (Communications Biology 3, 95, 2020), and pH-responsive upconversion mesoporous silica nanospheres for combined imaging and photothermal therapy in ACS Nano. Her own carrier is mesoporous polydopamine — and polydopamine's other well-known property is photothermal conversion. That is a real scientific bridge, not a stretched one.

There is no circular for this one, and there is not meant to be. Nothing is advertised in the Magzoub lab — this is a speculative approach to a named scientist, not an application to a posted vacancy. In drug delivery most postdoc posts are filled by direct contact before they are ever advertised, so the email is not a long shot; it is the standard route. Keep it under 200 words and attach one PDF.

NYUAD does have other postdocs open right now, checked 1 August 2026 — Biology (developmental biology), three in Chemistry, plus Physics, Mechanical Engineering, Data Science and CITIES. None is in her field: the Biology post is developmental, not cancer or delivery. Worth opening the listings yourself in case one of the Chemistry posts turns out to be delivery-adjacent, but do not let it delay the email.

Check the citation before sending. The Communications Biology details are solid. The ACS Nano volume and year came back inconsistent from the lab's own page, so the email refers to that paper by subject rather than by year. Getting a citation wrong in an email to the person who wrote it is the one unforced error worth avoiding.

∅ No circular — nothing advertised ✉ Open in mail client ↗ All live NYUAD postdocs ↗ Lab publications ↗ Faculty page ↓ CV — Academic (PDF)

The email — under 200 words by design

subject: Postdoc enquiry — mesoporous carriers for tumour-targeted co-delivery

Dear Dr Magzoub,

I completed a PhD in pharmaceutics at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and I am writing to ask whether you are considering postdoctoral researchers in your group.

Your Communications Biology paper on pH-responsive polymeric nanoparticles for targeted delivery of anticancer therapeutics is close to where my own work has led, and your mesoporous silica work on combined imaging and photothermal therapy is closer still — my doctoral carrier was a mesoporous polydopamine Pickering emulsion, and polydopamine's photothermal behaviour is a property I have not yet exploited.

That system co-delivered shikonin and the BET inhibitor JQ1 to triple-negative breast tumours, suppressing primary growth and lung metastasis by inducing apoptosis while blocking both epithelial-mesenchymal transition and vasculogenic mimicry. It is published in Acta Pharmacologica Sinica (46:3314-3326), where I am joint first author.

I run projects end to end — formulation and characterisation (DLS, zeta potential, TEM, HPLC), the cell biology behind the mechanism, and in vivo efficacy, biodistribution and toxicology in murine tumour models. Seven papers, 324 citations, one filed patent.

My CV is attached. I would welcome a short call if this is of interest.

With best regards,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics, Shanghai Institute of Materia Medica, CAS
doctordipikaoffical555@gmail.com | +971 50 965 9103
Google Scholar: 324 citations, h-index 3 | ORCID 0009-0007-0026-4638

Follow-up, if no reply after 10–14 days — send once only

one follow-up. Never two.

Dear Dr Magzoub,

I wrote a fortnight ago about postdoctoral possibilities in your group and wanted to put my note back at the top of your inbox in case it arrived at a busy time.

If you have no opening at present, I would still be glad to know whether you would consider supporting a fellowship application — I am happy to do the writing.

With best regards,

Dr. Dipika Ramdas Kalambhe

Checklist

Read the two papers named, at least the abstracts, so she can answer a reply
Confirm the ACS Nano citation if pinning it precisely
Attach the CV — one file, nothing else
Send from a mailbox she checks daily
Diarise the single follow-up for 10–14 days out

Speculative approaches

4 of 6

No advertised vacancy at any of these. Each is a direct approach to an employer worth being known to, lodged so that she is already in the system when something opens.

Khalifa University · College of Medicine & Health Sciences Speculative Abu Dhabi

Research fellow / postdoctoral enquiry

Contact recruitmentteam@ku.ac.ae Checked 1 Aug 2026 — nothing relevant open

The top-ranked university in the UAE, with wet-lab groups in its College of Medicine and Health Sciences. It has previously advertised a Genomics / Cancer Therapeutics postdoc requiring cell culture, qRT-PCR, Western blot, flow cytometry, confocal microscopy and mouse xenograft models — an almost exact description of her bench work. That post closed in December 2022, but it is proof they hire this profile.

What is not there. The nanoparticle postdoc that shows up in search results expired 28 February 2026 — and reading it in full shows it was a computational post (molecular dynamics, LAMMPS, MATLAB, FORTRAN). Simulation, not bench work. It would not have suited her even while open. Their portal is Oracle-based and cannot be read automatically, so open the careers hub yourself before sending.

Do this first. A speculative email to a generic HR address is the weakest thing in this pack. Spend twenty minutes on the CMHS faculty pages finding someone publishing on nanoparticles, drug delivery or cancer therapeutics, and write to them naming one of their papers — the NYUAD email above is the pattern. Send the HR message as well, not instead. One name worth checking as a starting point: Abdulrahman M. Elbagory, Department of Biological Sciences — unverified, confirm he is in post first.

∅ No circular — nothing relevant open ↗ Careers hub ↗ Find a PI in CMHS ✉ Open in mail client ↓ CV — Academic (PDF)

The email

for a general enquiry the email is the cover letter

Dear Recruitment Team,

I am writing to ask whether Khalifa University has, or expects, postdoctoral or research fellow openings in cancer nanomedicine or drug delivery within the College of Medicine and Health Sciences.

I completed a Ph.D. in pharmaceutics at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. My doctoral work co-delivered shikonin and the BET inhibitor JQ1 from a mesoporous polydopamine Pickering emulsion, which suppressed primary tumour growth and lung metastasis in triple-negative breast cancer models by inducing apoptosis while blocking both epithelial-mesenchymal transition and vasculogenic mimicry. It is published in Acta Pharmacologica Sinica (46:3314-3326), where I am joint first author.

I note that the University previously advertised a Post Doctoral Fellow in Genomics and Cancer Therapeutics requiring cell culture, qRT-PCR, Western blot, flow cytometry, confocal microscopy and mouse xenograft models. That is an accurate description of my daily bench work, which is why I am approaching Khalifa directly.

I hold seven peer-reviewed publications with 324 citations and one filed patent, and I am free to relocate to Abu Dhabi. My CV is attached. I would be grateful if it could be passed to any group leader for whom it is relevant.

With best regards,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics, Shanghai Institute of Materia Medica, CAS
doctordipikaoffical555@gmail.com | +971 50 965 9103
ORCID 0009-0007-0026-4638

Checklist

Open the careers hub in a browser and check for anything new
Identify a named PI in CMHS and write to them directly
Send the HR email with the CV attached
Diarise a re-check of the careers hub every two weeks

University of Sharjah · College of Pharmacy / SIMR General application Sharjah

Research fellow — general application + institute approach

Switchboard +971 6 5585000 (Mon–Thu 08:00–16:30) Checked both vacancy pages read in full, 1 Aug 2026

Worth being in the system: a College of Pharmacy, a large research footprint through the Sharjah Institute for Medical Research, and living costs materially below Dubai's. The university runs its own General Application route for exactly this situation.

Nothing open in her field, precisely. The six research vacancies are legal and judicial studies, water processing, modelling of evolutionary phenomena, civil infrastructure, supply-chain optimisation and nuclear energy simulation. The three academic vacancies are Audiology and Speech Language Pathology, Public Health and Medical Education. None is pharmacy, pharmaceutics or cancer.

Apply under research, not teaching. Gulf universities hire lecturers and assistant professors against 3–5 years of post-PhD teaching experience. Her doctorate was awarded in 2025, so teaching-titled applications will fail on that criterion alone however good the science. Research fellow and postdoctoral titles are the realistic ones.

∅ No circular — none in her field ↗ General Application ↗ Research vacancies ↗ Academic vacancies ↓ CV — ATS for portal (PDF) ↓ CV — Academic (PDF)

The email, to accompany the general application

upload the ATS CV to the portal; email the designed one

Dear Sir or Madam,

I have lodged a general application and am writing in parallel to ask whether the College of Pharmacy or the Sharjah Institute for Medical Research anticipates openings for a postdoctoral researcher or research fellow in drug delivery or cancer biology.

I completed a Ph.D. in pharmaceutics at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. My doctoral project co-delivered shikonin and the BET bromodomain inhibitor JQ1 from a mesoporous polydopamine Pickering emulsion, which suppressed primary tumour growth and lung metastasis in triple-negative breast cancer models by inducing apoptosis while blocking both epithelial-mesenchymal transition and vasculogenic mimicry. The work is published in Acta Pharmacologica Sinica (46:3314-3326), where I am joint first author, and I later incorporated the formulation into a thermosensitive hydrogel for use after tumour resection.

I work across the full preclinical range — formulation design and characterisation (DLS, zeta potential, TEM, SEM, HPLC, UV-Vis), the molecular and cell biology behind a mechanism, and in vivo efficacy, biodistribution and toxicology in murine tumour models. I hold seven peer-reviewed publications attracting 324 citations, and one filed Indian patent on a transdermal formulation.

I am also a qualified pharmacist with approximately three years of hospital practice, which I mention because it supports teaching that connects laboratory science to clinical use, should any teaching contribution be wanted alongside research.

My CV is attached and I would be glad to provide referee details. I am free to relocate to Sharjah.

Respectfully,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics, Shanghai Institute of Materia Medica, CAS
doctordipikaoffical555@gmail.com | +971 50 965 9103 | WhatsApp +91 97667 87348
ORCID 0009-0007-0026-4638

Checklist

Lodge the General Application, uploading the ATS CV
Keep the reference number — there is a "Track Your Application" box
Send the email separately with the designed CV
Write to named researchers at SIMR, citing a paper of theirs
Re-check both vacancy pages monthly

Julphar (Gulf Pharmaceutical Industries) · Ras Al Khaimah Speculative Ras Al Khaimah

Formulation R&D / product development — direct approach

Portal careers.julphar.net Checked all 27 RAK vacancies enumerated, 1 Aug 2026

The largest generic manufacturer in MENA and the most relevant industrial employer in the country for her. The hook is the patent: she took a formulation from concept through in vitro efficacy and in vivo safety evidence to a filed application, which is recognisably industrial product development rather than academic curiosity.

There is no R&D vacancy today. All 27 Ras Al Khaimah roles were read: procurement, engineering, HVAC, production, logistics, IT, internal audit, and three quality posts. The "Research Scientist" role quoted in the older dossier was search-sourced and is not advertised.

The nearest fit, Specialist – QC, asks for a bachelor's degree and "minimum 3-6 years' experience in the same field" — meaning cGMP quality control inside a plant. Her analytical skills genuinely overlap (HPLC, UV-Vis, assay, content uniformity, stability), but the experience is academic rather than GMP, and a PhD reads as overqualified for a bench QC post. Do not lead with it. If she would genuinely accept QC work, apply knowing it is a sideways move.

∅ No circular — no R&D role open ↗ Careers portal + talent network ↗ The QC post, for reference ↓ CV — Industry R&D (PDF) ↓ CV — ATS for portal (PDF)

Covering email

subject: Speculative enquiry — Formulation R&D, Ph.D. Pharmaceutics, named patent inventor

Dear Sir or Madam,

I am writing speculatively about research and development or product development roles at Julphar, and would be grateful if this could reach the R&D function.

I am a formulation scientist with a Ph.D. in pharmaceutics from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and eight years of hands-on development experience in nanoparticle and colloidal drug products — mesoporous carriers, Pickering emulsions, thermosensitive hydrogels and transdermal systems.

I am a named inventor on Indian patent application No. 202421042057 for a single-use transdermal system, which I took from formulation concept through in vitro efficacy and in vivo safety evidence to filing. That gave me direct experience of what an evidence package has to contain, and of building one to a deadline.

I hold a full Indian pharmacy qualification pathway alongside the doctorate — D.Pharm, B.Pharm and M.Pharm — with approximately three years of hospital pharmacy practice, so I understand how a product is stored, dispensed and used at the point of care. I am seeking to move into the UAE pharmaceutical industry and Ras Al Khaimah suits me well.

My CV and a covering letter are attached. I have also registered on your talent network. I would welcome a conversation whenever a suitable role opens.

With best regards,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics
doctordipikaoffical555@gmail.com | +971 50 965 9103
ORCID 0009-0007-0026-4638

Formal cover letter — attach as PDF

also adapts for the Dubai manufacturers below

Dr. Dipika Ramdas Kalambhe, Ph.D.
doctordipikaoffical555@gmail.com | +971 50 965 9103 | WhatsApp +91 97667 87348
ORCID 0009-0007-0026-4638

1 August 2026

Research & Development
Gulf Pharmaceutical Industries (Julphar)
Ras Al Khaimah, United Arab Emirates

Dear Sir or Madam,

I am writing to express my interest in formulation research and development at Julphar.

I am a formulation scientist with a Ph.D. in pharmaceutics from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and eight years of hands-on development experience in nanoparticle and colloidal drug products. My work has spanned mesoporous carriers, Pickering emulsions, thermosensitive hydrogels and transdermal systems, taken from formulation concept through to preclinical proof of concept.

Concretely, what that has meant day to day: developing a carrier that co-encapsulates two chemically dissimilar actives and systematically optimising composition, drug ratio, drug loading, encapsulation efficiency, particle size and polydispersity, colloidal stability and release profile; characterising every batch against a defined specification set by DLS, zeta potential, TEM, SEM, HPLC and UV-Vis; establishing stability across storage conditions; and carrying the lead candidate through in vivo efficacy, biodistribution and organ-toxicity evaluation. Formulation development, analytical characterisation and study execution have all been in my own hands rather than passed between teams.

I am also a named inventor on Indian patent application No. 202421042057, a single-use transdermal delivery system for a turmeric flavonoid fraction. I took that formulation from concept through in vitro efficacy and in vivo safety evidence to filing, and published the supporting study in the Journal of Pharmaceutical Innovation as first author. That work is the closest thing in my record to industrial product development: a defined product, an evidence package assembled to support it, and a filing at the end of it.

Why Julphar specifically. It is the largest generic manufacturer in the region and the most substantial pharmaceutical R&D presence in the UAE, and its portfolio is aimed at chronic disease in this market rather than at a global average patient. Formulation work with a defined population behind it is more interesting to me than platform work in the abstract. I am seeking to build my career in the Emirates, and Ras Al Khaimah suits me both professionally and practically.

I should be straightforward about the boundary of my experience. My development work has been in a research institute, not in a cGMP manufacturing environment, so I have not run process validation, scale-up or commercial batch release. What I would bring is the front end — formulation design, optimisation against competing physicochemical constraints, analytical method work, and the discipline of building an evidence package that will be read by someone outside the laboratory. I learn instrumentation and process quickly; the full analytical toolkit I use now was built from nothing during my doctorate.

Alongside the doctorate I hold the complete Indian pharmacy qualification pathway — D.Pharm, B.Pharm and M.Pharm in Pharmaceutics — and approximately three years of hospital pharmacy practice in a multispeciality nephrology hospital. That means I have seen the end of the chain: how a product is actually stored, dispensed, explained to a patient and, occasionally, got wrong.

I have seven peer-reviewed publications attracting 324 citations, including reviews on additive manufacturing in nano drug delivery and on 3D printing for oral dosage materials, both of which touch directly on manufacturability.

I would welcome the opportunity to discuss where my experience might be useful, whether now or when a suitable position opens.

Yours faithfully,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics | M.Pharm | B.Pharm | D.Pharm

Checklist

Register on the talent network and set an alert
Search the portal for "research", "formulation", "development" before sending
Send the speculative letter with the Industry CV
Decide deliberately about Specialist – QC; do not drift into it
Re-check the portal fortnightly

Pharmax Pharmaceuticals & Globalpharma · Dubai Speculative Dubai

Formulation R&D — LinkedIn-led approach to two manufacturers

Pharmax Dubai Science Park · AED 125m plant · branded generics Globalpharma Dubai Investments subsidiary · broad generic portfolio

Dubai has the most pharmaceutical employers of the four emirates and the fewest that publish research vacancies. Neither company advertises formulation R&D on a page readable from outside, so the route in is a direct approach — LinkedIn first, then email.

Dubai's more reliable route is not this one. It is clinical pharmacy in a hospital group, via DHA licensing — where she already qualifies. See the strategy panel below. Start that in parallel, because the verification step is slow and nothing else moves until it finishes.

∅ No circular — nothing published ↗ Pharmax on LinkedIn ☰ Full notes + per-company paragraphs ↓ CV — Industry R&D (PDF)

The email — replace [COMPANY] and the addressee

send separately to each company, never as one message

Dear [NAME / Sir or Madam],

I am writing to ask whether [COMPANY] has openings, now or in prospect, in formulation research and development or product development.

I am a formulation scientist with a Ph.D. in pharmaceutics from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and eight years of hands-on development experience in nanoparticle and colloidal drug products — mesoporous carriers, Pickering emulsions, thermosensitive hydrogels and transdermal systems. I am a named inventor on Indian patent application No. 202421042057, which I took from formulation concept through in vitro efficacy and in vivo safety evidence to filing.

Alongside the doctorate I hold D.Pharm, B.Pharm and M.Pharm qualifications and around three years of hospital pharmacy practice, so I understand both ends of the chain — how a product is developed and how it is finally dispensed and used.

I have seven peer-reviewed publications attracting 324 citations, including reviews on additive manufacturing in nano drug delivery and 3D printing for oral dosage materials.

My CV and covering letter are attached. I would welcome a conversation.

With best regards,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics
doctordipikaoffical555@gmail.com | +971 50 965 9103
ORCID 0009-0007-0026-4638

Checklist

Find the R&D lead at each company on LinkedIn
Send connection notes, then full messages once connected
Adapt the Julphar letter with the right per-company paragraph
Set a LinkedIn alert for formulation and R&D roles in Dubai
Start DHA licensing in parallel

Advertised, but a long shot

1 of 7

A live post at the right university, with terms worth having — and a requirement she misses by six years. Included because it is real and because the enquiry email costs nothing, not because the application is likely to succeed.

NYU Abu Dhabi · Division of Science (Biology) Live advert Long shot Abu Dhabi

Research Scientist — gene expression in circadian neural networks

PIs Dipesh Chaudhury & Justin Blau Opened 15 Jul 2026 · until filled Questions nyuad.neurosystems@nyu.edu

Terms are strong — competitive salary, housing, children's education subsidies, relocation allowance — and the responsibilities include real overlap: mouse brain immunohistochemistry, gene expression work, and in vivo mouse experiments, all of which are daily work for her.

She does not meet the stated bar, and the gap is not one a cover letter closes. The advert requires, verbatim, "at least six years research experience in Circadian Biology post PhD" — she is one year post-PhD with no circadian background at all — and "knowledge in advanced electrophysiological techniques", of which she has none. Stereotaxic brain surgery, slice electrophysiology, single-cell and bulk RNA sequencing and spatial genomics are all absent too. She clears two of the nine listed requirements.

It also demands a degree transcript and two letters of recommendation. That means spending Prof. Huang's first letter of the year on a post she cannot win — and she will need him for UAEU and for an MSCA host. Recommendation: send the enquiry email only.

The smart move costs nothing. nyuad.neurosystems@nyu.edu is published for questions. Ask directly whether they would consider someone without the circadian background. One word back, in days, no referee goodwill spent. If yes, the full application is ready and waiting. If no reply in two weeks, that is the answer — put the effort into the Magzoub email instead, at the same university.

↗ Open the circular ↓ Cover letter (PDF) ↓ Research statement (PDF) ↓ CV — Bioscience (PDF) ☰ Full notes

The enquiry email — send this instead of the full application

to nyuad.neurosystems@nyu.edu · no attachments needed

Subject: Research Scientist, circadian neural networks — eligibility question before applying

Dear Professor Chaudhury and Professor Blau,

I am writing about the Research Scientist post on gene expression in circadian neural networks, before preparing a full application, because I would rather ask a direct question than take up your committee's time.

The advertisement asks for at least six years of post-PhD research experience in circadian biology and knowledge of advanced electrophysiological techniques. I have neither. I completed a PhD in pharmaceutics at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2025, and my field is cancer biology and targeted drug delivery. I have no circadian background and no electrophysiology.

What I do bring is the molecular and in vivo half of your list, built over eight years and run independently: murine studies including ethics approval, dosing, longitudinal monitoring, terminal tissue collection, histopathology and immunohistochemistry; gene and protein expression work by RT-qPCR, Western blot, ELISA, flow cytometry and immunofluorescence; and confocal and fluorescence microscopy. My doctoral work established that a combination therapy suppressed tumour growth and metastasis by inducing apoptosis while blocking epithelial-mesenchymal transition and vasculogenic mimicry, published in Acta Pharmacologica Sinica where I am joint first author.

My question is simply whether you would consider a candidate who would need to learn slice electrophysiology and the circadian literature from the beginning, but who arrives fluent in the molecular and in vivo techniques on your list. If the answer is no, I completely understand, and I would rather know before asking my referees to write.

If it is worth a conversation, my CV and portfolio are below and I can send the full application immediately.

With best regards,

Dr. Dipika Ramdas Kalambhe
Ph.D. Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
doctordipikaoffical555@gmail.com | +971 50 965 9103
Portfolio: https://dipika.pristellar.com
Google Scholar: 324 citations, h-index 3 | ORCID 0009-0007-0026-4638

Checklist

Send the enquiry email — and wait for a reply
Do NOT ask Prof. Huang for a letter until they reply
Request the degree transcript from SIMM — needed for other applications anyway
If they reply yes: set up the free Interfolio Dossier account so letters can be reused
If no reply in two weeks: stop, and send the Magzoub email instead

Strategy

Why the list looks the way it does, and what to do beyond sending these six.

The market, stated plainly

Six targets were built and one answers a live advertisement. That ratio is not a shortcut. Every UAE university careers portal and the country's largest pharmaceutical employer were opened and enumerated on 1 August 2026.

Employer	What is open	Fits her?
UAEU (Al Ain)	Postdoc — targeted delivery of epigenetic inhibitors	Yes — apply
University of Sharjah	6 research, 3 teaching posts	No — water, nuclear, civil, supply chains, law, audiology, public health
Khalifa University	Nuclear engineering postdoc	No. The nanoparticle postdoc expired Feb 2026 and was computational
RAKMHSU	Pharmacology professorship	No — requires an MBBS/MD and 3 years post-PhD teaching
Julphar (RAK)	27 roles — procurement, engineering, production, QC/QA	No R&D or formulation role at all
Pharmax / Globalpharma	Nothing published	—

The UAE has few research universities, and its pharmaceutical industry is manufacturing-led rather than discovery-led — Julphar makes generics extremely well, but it does not run a discovery pipeline that needs her background. The response is to stop refreshing job boards and start writing to people. In drug delivery most postdoc posts are filled by direct contact before they are advertised.

Two barriers worth knowing now

Faculty posts need teaching experience she does not have. Gulf universities hire lecturers and assistant professors against 3–5 years of post-PhD teaching. Her doctorate was awarded in 2025. No publication record substitutes for it. Aim at research titles — postdoctoral fellow, research fellow, research associate.

The Golden Visa scientist route is closed to her. It requires an h-index of 10 or above; hers is 3. This matters because agencies sell "Golden Visa eligibility assessments" to exactly this profile. An h-index of 10 typically takes a decade. What is open is an ordinary employer-sponsored employment residence visa, which is how nearly everyone works in the UAE and requires nothing exceptional.

Medical Science Liaison roles are also not a near-term route — live Gulf postings require 3–5 years of pharmaceutical industry experience, which she does not have.

Her most reliable UAE route, and it is not a research post

Hospital pharmacy, via licensing. She is a qualified pharmacist with roughly three years of hospital practice, and this is the one thing in her record the UAE market wants today without argument. Licensing is emirate-specific, so the emirate must be chosen before any money is spent.

Emirate	Regulator
Dubai	DHA — Dubai Health Authority
Abu Dhabi (incl. Al Ain)	DOH — Department of Health
Sharjah, Ras Al Khaimah, northern emirates	MOHAP — federal Ministry of Health and Prevention

For DHA the bar is an accredited B.Pharm, M.Pharm or PharmD plus two years of post-qualification hospital or retail experience. She meets it — her hospital periods total about three years, and hospital experience is exactly what counts.

Primary Source Verification (DataFlow) — degrees and experience verified with the issuing institutions. The slow step. Start it before anything else.
Prometric examination — sittable in India, no travel required.
Good standing certificate from her state pharmacy council.
Occasionally a short oral assessment by video.

Her PhD is an advantage here, not an oddity — for an oncology or clinical pharmacy post, a doctorate with published work on cytotoxic and targeted agents is genuinely distinguishing. Employers to approach once licensing is under way: Cleveland Clinic Abu Dhabi, SEHA, Dubai Health, Mediclinic, Burjeel, NMC, Aster DM, King's College Hospital London Dubai.

Start the attestation chain at the same time. Her Chinese PhD certificate needs attestation — Ministry of Foreign Affairs in China, then the UAE Embassy there, then UAE MOFA. Slow, required for any employment visa, and can run in parallel.

Order of play

This week

Submit the UAEU application — closes 31 August, do not leave it to the last week.
Send the NYUAD email to Dr Magzoub. The highest-value message in this pack.
Open the DataFlow / PSV file for whichever emirate she is targeting.
Begin attestation of the PhD certificate.

Next two weeks

Khalifa — find a named PI, write to them, and send the HR enquiry as well.
Sharjah — lodge the General Application, then write to named SIMR researchers.
Julphar — register on the talent network, send the speculative letter.
Dubai — identify R&D leads at Pharmax and Globalpharma on LinkedIn.

Ongoing. Re-check every portal fortnightly; they change without notice. One follow-up per cold email after 10–14 days. One, never two.

Money, roughly

No personal income tax in the UAE. Indicative and unverified: university research and academic staff AED 10,000–35,000 a month depending on rank; clinical pharmacist AED 12,000–25,000; mid-level industry research scientist of the order of AED 100,000–150,000 a year. Use these to sanity-check an offer, not to negotiate from.

Housing is the largest variable. Dubai is the most expensive of the four emirates; Sharjah and Ras Al Khaimah are materially cheaper. A lower salary in RAK can leave more at the end of the month than a higher one in Dubai.

Recruitment fraud. Julphar publishes a fraud warning on its own site, which tells you how common this is. No legitimate UAE employer asks a candidate to pay for a visa, a medical, a training course, a "processing fee" or an "application review". Any request for money in connection with a job is a scam, every time, without exception. This is the most common way overseas applicants to the Gulf lose money.

Two things that must be settled before anything is sent

Both are open in HANDOFF.md §4 and only Dipika can answer them.

The 2020–2022 hospital pharmacist period that overlaps her doctorate. Every CV carries a line explaining it as COVID border closures. That is an inference. If it is wrong it must be corrected now — an interviewer will ask, and a wrong explanation is worse than an unexplained gap.
The Mandarin claim. Listed as conversational, inferred from eight years in Shanghai. An interviewer may simply switch languages to check.

Also worth asking her: whether she has any unpublished hands-on lipid-nanoparticle work. The published record does not support the claim her original CV made, and several target labs ask for it by name.

One thing not to give up while doing this

The MSCA Postdoctoral Fellowship closes 9 September 2026 and needs a host supervisor secured well before then. It remains the most valuable single opportunity in her whole search, and the cold emails that secure a host cost an evening each.

Pursuing the UAE does not require abandoning it — the two campaigns share the same CV and nearly the same email. If the UAE approaches go quiet through August, which on the evidence above is a real possibility, the European track is what stops that month being wasted.

A note on the CVs

All 20 CV files were rebuilt on 1 August. Every CV had been printing a link to a private, outdated page into its contact line; that link is now removed. Put the real URL back in _source/cv_data.py the moment the portfolio is deployed, then rebuild.

Her email address was deliberately not changed — doctordipikaoffical555@gmail.com is her real working mailbox, and replacing it needs a new account to exist first. It is one line to change when she is ready.